Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.58 |
| ▸ | PPARA | Q07869 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GRN | P28799 | 1/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 4/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510174 | 1.00 | PPARG (0.58) | PPARGPPARAALDH1A1MAPTPPARD | |
| SCHEMBL4502068 | 0.93 | PPARA (0.64) | PPARGPPARAALDH1A1MAPTPPARD | |
| SCHEMBL4502065 | 0.93 | PPARA (0.64) | PPARGPPARAALDH1A1MAPTPPARD | |
| SCHEMBL3626360 | 0.89 | ALDH1A1 (0.56) | PPARGPPARAALDH1A1MAPTTSHR | |
| SCHEMBL2585108 | 0.89 | ALDH1A1 (0.56) | PPARGPPARAALDH1A1MAPTTSHR | |
| SCHEMBL4092761 | 0.88 | CTSS (0.49) | PPARGPPARAALDH1A1PPARDTSHR | |
| SCHEMBL4092754 | 0.88 | CTSS (0.49) | PPARGPPARAALDH1A1PPARDTSHR | |
| SCHEMBL4510911 | 0.85 | PPARA (0.45) | PPARGPPARAALDH1A1PPARDTSHR | |
| SCHEMBL4510905 | 0.85 | PPARA (0.45) | PPARGPPARAALDH1A1PPARDTSHR | |
| SCHEMBL3719212 | 0.83 | PPARA (0.60) | PPARGPPARAALDH1A1MAPTPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953158-B1 | BICYCLIC CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | APP, BACE1, PSEN1 | PPARG 2812/4885PPARA 1582/4885ALDH1A1 869/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | PPARG 2812/4885PPARA 1582/4885ALDH1A1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.